{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:26:33Z","timestamp":1781760393998,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T00:00:00Z","timestamp":1592697600000},"content-version":"am","delay-in-days":386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.canrad.2018.12.005","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T16:58:50Z","timestamp":1558976330000},"page":"232-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Radiotherapy in combination with nivolumab for relapsed\/refractory classical Hodgkin lymphoma: About two cases"],"prefix":"10.1016","volume":"23","author":[{"given":"L.","family":"de Forceville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Deau-Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ars\u00e8ne-Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cassou Mounat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bouscary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.M.","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2018.12.005_bib0145","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2018.12.005_bib0150","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","article-title":"Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation","volume":"24","author":"Mart\u00ednez","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0155","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0160","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2018.12.005_bib0165","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bjh.15184","article-title":"Tandem haematopoietic stem cell transplantation for High Risk relapsed\/refractory Hodgkin lymphoma: a LYSA study","volume":"181","author":"Deau","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0170","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/annonc\/mdw169","article-title":"Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes","volume":"27","author":"Cheah","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0175","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0180","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0185","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0360-3016(97)00352-0","article-title":"Salvage radiotherapy for Hodgkin's disease following chemotherapy failure","volume":"39","author":"Wirth","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.12.005_bib0190","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V80.8.2142.2142","article-title":"Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up","volume":"80","author":"Vose","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.12.005_bib0195","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2005.05.022","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0200","first-page":"1428","article-title":"Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed\/refractory classical Hodgkin lymphoma: the Transplant BRaVE study","volume":"36","author":"Hagenbeek","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.canrad.2018.12.005_bib0205","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.12.005_bib0210","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17474086.2018.1449637","article-title":"Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma","volume":"11","author":"Kallam","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0220","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canrad.2018.12.005_bib0225","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2018.12.005_bib0230","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.12.005_bib0235","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijrobp.2012.03.017","article-title":"The abscopal effect associated with a systemic anti-melanoma immune response","volume":"85","author":"Stamell","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.12.005_bib0240","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2018.12.005_bib0245","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00262-015-1771-8","article-title":"Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors","volume":"65","author":"Derer","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.canrad.2018.12.005_bib0250","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0255","first-page":"91","article-title":"Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody","volume":"66","author":"Michot","year":"2016","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.canrad.2018.12.005_bib0260","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1667\/RR15048.1","article-title":"Complete local and abscopal responses from a combination of radiation and nivolumab in refractory Hodgkin's lymphoma","volume":"190","author":"Qin","year":"2018","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2018.12.005_bib0265","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.12.005_bib0270","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00066-016-1050-4","article-title":"Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma","volume":"193","author":"Baues","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2018.12.005_bib0275","first-page":"2166","article-title":"Cost effectiveness of nivolumab for the treatment of relapsed\/refractory Classical Hodgkin Lymphoma (cHL) after failure of Autologous Stem Cell Transplantation (ASCT) and treatment with Brentuximab Vedotin (BV) treatment in Australia","volume":"130","author":"Tan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.12.005_bib0280","doi-asserted-by":"crossref","first-page":"A433","DOI":"10.1016\/j.jval.2017.08.203","article-title":"The cost-effectiveness of nivolumab for the treatment of people with relapsed or refractory classical Hodgkin lymphoma following autologous stem cell transplant and brentuximab vedotin","volume":"20","author":"Jones","year":"2017","journal-title":"Value Health"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819300861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819300861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:30:34Z","timestamp":1761136234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321819300861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1278321819300861"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2018.12.005","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy in combination with nivolumab for relapsed\/refractory classical Hodgkin lymphoma: About two cases","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2018.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}